Testicular germ cell tumours (GCTs) mostly affect young men at age 17-40.
| INTRODUCTION
Testicular type II germ cell tumours (GCTs), which are sub-divided into seminomas and non-seminomas, arise from the precursor lesion germ cell neoplasia in situ (GCNIS).
1,2 GCNIS and seminoma cells are highly similar to primordial germ cells with regard to histology, gene expression and epigenetics, while the stem cell population of the non-seminomas, the embryonal carcinoma (EC), shows features of pluri-to totipotency. 1 Thus, ECs are able to differentiate into cells of all germ layers (teratoma) and into cells resembling extra-embryonic tissues (yolk-sac tumours, choriocarcinomas). 1 Generally, GCTs are treated by orchiectomy followed by additional chemotherapy. By this, high cure rates of >90% are achieved, however, patients with metastatic disease or resistance towards standard chemotherapy require alternative therapeutic options. 3 In previous studies, we demonstrated that treatment of (cisplatin-resistant) GCT cell lines with the histone deacetylase inhibitor (HDACi) romidepsin (ISTODAX, FR228, FR901228) efficiently induced apoptosis and blocked the cell cycle at very low doses, but did not affect survival of fibroblasts or Sertoli cells. [4] [5] [6] We showed that romidepsin treatment of GCT cell lines resulted in heterochromatin formation within the promotor of ARID1A causing down-regulation of ARID1A, 5 which is a subunit of the chromatin remodelling SWI/SNF-complex. As a result, stress and apoptosis sensors as well as cell cycle regulators GADD45B, ATF3, ZFP36, DUSP1, FOS, ID2
and CDKN1A were up-regulated. 5 In addition, we identified four genes (DHRS2, RHOB, CRISPLD2, BAIAP2), which were up-regulated in all GCT cell lines tested as well as the controls (fibroblasts and the Sertoli cell line FS1), suggesting that these genes represent a common effect of romidepsin on gene expression. 5 Among all samples analysed, DHRS2 was the most prominently up-regulated gene. 5 In this study, we extended our analysis of the molecular mode of action of romidepsin and also focused on the role of DHRS2, a NADPHdependent dehydrogenase/reductase, in the romidepsin-response cascade, to gain a better understanding of the effects of romidepsin on GCTs and normal healthy cells. In general, understanding the molecular effects of a therapeutic drug is required for the assessment of risks and side effects before administering it to a patient.
| MATERIALS AND METHODS

| Cell culture
All cell lines used as GCT proxies (TCam-2, seminoma; 2102EP, EC; NCCIT; extra-gonadal derived EC; JAR, placenta-derived choriocarcinoma), fibroblasts (MPAF) and Sertoli cells (FS1) used in this study were cultivated as described previously. 5 
| Generation of DHRS2-deficient TCam-2 cells
TCam-2 cells heterozygous or homozygous deficient for DHRS2 were generated as published. 5, 8 Deletions within the coding sequence of DHRS2 in each clone were detected by PCR ( Figure S1C ,D). See Table 1 for guideRNA sequences and genotyping primers.
| DNA, RNA and protein isolation
Genomic DNA, total RNA and proteins were isolated as described previously. 5 Briefly, DNA was isolated by phenol/chloroform/isoamylalcohol precipitation, RNA by the RNAeasy mini kit (Qiagen, Hilden, Germany) and proteins by RIPA buffer.
| Western blot
Western blots were performed as described previously. 5 Beta-ACTIN was used as housekeeper and loading control. See Table 2 for antibody details.
| Quantitative RT-PCR
Quantitative RT-PCR was performed as published previously.
5 500 ng of total RNA was used for first strand synthesis. GAPDH was used as housekeeping gene and for data normalisation. In general, all samples were analysed in technical triplicates and biological triplicates/quadruplicates (see individual figure legend for more detailed information).
| Quantification of DNA methylation levels
DNA methylation (5mC) levels were quantified as published using the 2.8 | FACS-based propidium iodide and AnnexinV/ 7AAD measurement FACS-based measurement of cell cycle distribution and apoptosis levels were performed as described previously. 5, 6 All samples were analysed in technical and biological triplicates.
| XTT assay
The XTT assay was performed as described previously. 
| Chromatin immunoprecipitation followed by sequencing
Data of the chromatin immunoprecipitation followed by sequencing experiment are publically available via GEO (GSE78262) and were re-analysed in context of this study. The Illumina expression and DNA methylation array analyses were performed exactly as published. 5, 9 The microarray data sets are available via GEO (ncbi.nlm.nih.gov/geo/) (GSE76709; GSE71239; Data S1E).
| Affymetrix expression microarray analysis of GCT tissues
The whole procedure has already been published. 10 The array was re-analysed in context of this study.
| Statistics
We checked for significance of measured values by performing twotailed Student's t-tests. Significance was assumed at P ≤0.05. For all measurements, standard deviations were calculated and given above the bars.
| RESULTS
Previously, we demonstrated that romidepsin causes global hyperacetylation of histones 3 and 4. 5 Now, we addressed the question, whether romidepsin treatment elicits an alteration at specific lysine residues and acts in a cell-type specific manner. We used western blotting to screen for changes in lysine acetylation on histones H3
and H4 16 hours after romidepsin application ( Figure 1A ). General efficacy of the romidepsin treatment was validated by detection of pan-H3 and -H4 acetylation. GCT cell lines (TCam-2, 2012EP, JAR) showed considerably higher levels of acetylation compared to human fibroblasts (MPAF). Within the group of GCT samples, non-seminomatous cell lines (2102EP, JAR) showed highest levels of acetylation at all analysed H3-and H4-lysine residues. Four lysine residues (H3K4, H3K14, H3K79, H4K16) showed an increase in acetylation in non-seminomatous cell lines only. Although, the overall increase in acetylation at these lysines was low compared to the other lysine residues analysed. H4K8 acetylation was low before and remained low after romidepsin treatment in all tested cell lines. No lysine residue could be identified that showed a specific increase in acetylation in TCam-2 or MPAF cells. Fibroblasts did not respond as strongly as GCT cells to romidepsin, which is in line with the strongly reduced induction of apoptosis in fibroblasts compared to GCT cells. 5 We analysed if the increase in histone acetylation might also affect the DNA methylation (5-methylcytosine; 5mC) landscape. It has been proposed that acetylated histones are associated with unmethylated DNA and methyated DNA is able to recruit HDACs to repress transcription. 11 In addition, in a previous study we demonstrated that GCT cell lines are able to actively demethylate their DNA via the oxidative pathway involving the TET enzymes, allowing for a rapid change in the 5mC pattern. 12 We performed 5mC microarray analysis (Illumina 450k) and an ELISA-based quantification of global 5mC levels, but could not detect any significant differences in global 5mC levels of TCam-2, 50% change in 5mC to control) (Data S1A).
In our previous study, we observed that DHRS2 was the most prominently up-regulated gene in response to romidepsin in GCT cell lines, prompting us to analyse the role of DHRS2 in more detail.
5
DHRS2 is a NADPH-dependent dehydrogenase/reductase with 3,4-hexanedione, 2,3-heptanedione and 1-phenyl-1,2-propanedione as substrates. DHRS2 has been shown to attenuate MDM2-mediated P53 degradation, leading to P53 stabilisation and MDM2/P21 accumulation. 13 First, we demonstrated that DHRS2 is not expressed in different GCT tissues and normal testis tissues ( Figure S1 ). Furthermore, we demonstrated previously that DHRS2 is also absent in GCT cell lines and strongly induced upon romidepsin treatment of (cisplatin-resistant) GCT cell lines, fibroblasts (MPAF and ARZ) and Sertoli cells (FS1). 5 Thus, up-regulation of DHRS2 is a common effect provoked by romidepsin.
Of note, we screened for changes in expression of other DHRS genes in response to romidepsin in GCT cell lines, including the important DHRS2 paralogue DHRS4 ( Figure S1B ). We found that,
besides DHRS2, expression levels of all other DHRS molecules analysed remained either unchanged or were down-regulated upon romidepsin treatment, suggesting that the other DHRS genes are not involved in the romidepsin response ( Figure S1B ).
We asked how DHRS2 expression might be regulated in GCTs.
As shown by chromatin-immunoprecipitation followed by sequencing in TCam-2 cells 16 hours after romidepsin treatment, the induction of DHRS2 was accompanied by an increase in histone H3 acetylation 
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